Jubilant Pharmova (JUBLPHARMA) — Financial Results

Investor Takeaways

Reported Q3FY25 revenue of ₹1,821.7 Cr, up from ₹1,752.3 Cr in Q2FY25 and ₹1,731.7 Cr in Q1FY25.

Q3FY25 net profit was ₹100.7 Cr, compared to ₹102.5 Cr in Q2FY25 and ₹481.8 Cr in Q1FY25.

Q3FY25 operating profit margin (OPM) stood at 15.78%, slightly below Q2FY25's 16.52% but above Q4FY24's 15.43%.

⚠️ No specific risks identified in this filing.

Overall Tone: Neutral based on the numbers only.

Key Financial Highlights

Metric	Value	YoY Change
Revenue	₹1,821.7 Cr	4.8% increase from Q2FY25; 5.3% increase from Q1FY25
Net Profit	₹100.7 Cr	1.6% decrease from Q2FY25; 79.0% decrease from Q1FY25
EBITDA	Not available	Not available
EPS	[amount context mismatch]	Not comparable to Q1FY25's ₹30.44 due to share structure
OPM	15.78%	Slightly lower than Q2FY25's 16.52%

What Changed

The company demonstrated sequential revenue growth, with Q3FY25 revenue rising to ₹1,821.7 Cr from ₹1,752.3 Cr in the previous quarter (Q2FY25) and ₹1,731.7 Cr in Q1FY25. However, net profit declined significantly year-on-year from ₹481.8 Cr in Q1FY25 to ₹100.7 Cr in Q3FY25, indicating a sharp drop in profitability despite revenue growth. Operating profit margin (OPM) remained relatively stable at 15.78% in Q3FY25, marginally down from 16.52% in Q2FY25 but improved from 15.43% in Q4FY24. The earnings per share (EPS) of ₹6.37 in Q3FY25 reflects a substantial reduction compared to ₹30.44 in Q1FY25, primarily due to differences in share count or accounting adjustments. Overall, the quarter showed revenue expansion but a notable contraction in net earnings, suggesting potential pressure on margins or cost management.

Peer Comparison

Company	P/E	ROE	ROCE	Market Cap (₹ Cr)
Jubilant Pharmova Limited	25.01	Not provided	Not provided	15,771.22
Sun Pharmaceutical Industries Limited	41.28	15.11%	20.34%	4,50,643.09
Divi's Laboratories Limited	72.41	16.56%	22.09%	1,79,470.03
Torrent Pharmaceuticals Limited	80.06	N/A	N/A	1,49,108.91

Jubilant Pharmova trades at a significantly lower P/E ratio compared to its peers, suggesting potentially lower growth expectations or valuation discounts. However, peer return on equity (ROE) and return on capital employed (ROCE) metrics are not directly comparable due to missing data for Jubilant. The company's market capitalization is substantially smaller than Sun Pharmaceutical but comparable to Divi's and Torrent.

Risks & Concerns

No specific risks identified in this filing.

Quarterly Trend

Quarter	Revenue (₹ Cr)	Net Profit (₹ Cr)	OPM%
Q3FY25	1,821.7	100.7	15.78
Q2FY25	1,752.3	102.5	16.52
Q1FY25	1,731.7	481.8	14.52
Q4FY24	1,758.6	-61.8	15.43

📄 View Original Announcement (PDF)

📊 Stock Analysis — JUBLPHARMA ✨ Ask AI About This

About Jubilant Pharmova Limited (JUBLPHARMA)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹14,469.9 Cr P/E: 40.9 ROE: 5.0% ROCE: 7.4% Div Yield: 0.55%

View full JUBLPHARMA stock details →

📡 Get AI alerts when JUBLPHARMA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track JUBLPHARMA — Free

💡 Ask AI about this filing

"When will Q1 FY27 results be filed?" "What are the key discussion points with investors?" "How does this meeting impact JUBLPHARMA's valuation?"

Ask AI Free →

📊 More JUBLPHARMA filings

See all JUBLPHARMA filings →

🔥 Also filed on 5 August 2026

MAYURUNIQ Mayur Uniquoters Ltd Annual Report BEL Bharat Electronics Limited Corporate Action KIMS Krishna Institute of Medical Sciences Limited Annual Report RPTECH Rashi Peripherals Limited Financial Results RELINFRA Reliance Infrastructure Limited Announcement GREAVESCOT Greaves Cotton Limited Financial Results

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when JUBLPHARMA files new disclosures

Track JUBLPHARMA filings, board meetings, and corporate actions. Free email alerts at 5 PM.